Skip to main content

Alecnib 150 mg ( Alectinib)

Alecnib is identified on this website as a medicine containing alectinib, with a stated strength of 150 mg. Alectinib is a targeted anticancer medicine used to treat specific types of non-small cell lung cancer (NSCLC) that test positive for an abnormality involving the anaplastic lymphoma kinase (ALK) gene.

Unlike conventional chemotherapy, alectinib belongs to a group of targeted medicines known as ALK tyrosine kinase inhibitors. It works by blocking abnormal ALK signaling that can contribute to cancer-cell growth and survival.

Alecnib is intended for informational discussion of alectinib treatment. The exact manufacturer, regulatory authorization, formulation and product-specific characteristics of Alecnib should be confirmed from its actual packaging and official documentation.

What Is Alecnib?

Alecnib is identified as an alectinib-containing product with a stated strength of 150 mg. Alectinib is an oral targeted therapy prescribed for eligible patients with ALK-positive NSCLC.

ALK-positive lung cancer is a type of cancer in which a genetic change causes abnormal activity of the ALK protein. This abnormal signaling can encourage cancer cells to grow and multiply.

Alectinib selectively inhibits ALK and helps interfere with the signals that support cancer-cell growth.

Treatment is generally considered when appropriate molecular testing confirms ALK-positive disease and the patient meets the applicable treatment criteria.

Active Ingredient: Alectinib

The active ingredient identified for Alecnib is alectinib.

Alectinib is a selective ALK inhibitor. It is designed to block the activity of abnormal ALK proteins associated with certain cancers.

Its targeted action makes it different from traditional chemotherapy medicines, which generally affect a wider range of rapidly dividing cells.

Alectinib also has activity against certain other kinases, including RET, but its principal clinical role is the treatment of ALK-positive NSCLC.

What Is Alecnib Used For?

Alectinib is used for specified patients with ALK-positive non-small cell lung cancer.

Depending on the applicable country’s regulatory authorization and clinical circumstances, treatment may include:

1. Adjuvant treatment after lung cancer surgery

Alectinib may be used after surgical removal of qualifying ALK-positive NSCLC to reduce the risk of cancer returning.

In the United States, the reference-product indication includes adjuvant treatment following tumor resection for adults with ALK-positive NSCLC whose tumors meet specified size or lymph-node criteria.

The treatment duration and eligibility should be determined according to the applicable prescribing information and oncology assessment.

2. Metastatic ALK-positive NSCLC

Alectinib is also used for eligible adults with ALK-positive NSCLC that has spread to other parts of the body.

Metastatic disease means that cancer has moved beyond its original location. Treatment aims to control cancer growth and help manage the disease.

3. ALK-positive lung cancer involving the brain

Some patients with ALK-positive NSCLC develop cancer spread to the brain.

Alectinib can reach the central nervous system and has demonstrated activity against certain brain metastases. However, individual responses vary, and treatment requires appropriate imaging and specialist monitoring.

Important: Alecnib should not be considered a treatment for every type of lung cancer. ALK-positive status must be established through an appropriate validated molecular test.

How Does Alecnib Work?

Alectinib works by inhibiting abnormal ALK tyrosine kinase activity.

In some lung cancers, a genetic rearrangement involving the ALK gene creates an abnormal fusion protein. This protein can remain active and send signals that promote cancer-cell growth and survival.

Alectinib blocks the activity of this abnormal protein.

Its mechanism can be understood through the following steps:

  1. ALK abnormality develops: A genetic change creates an abnormal ALK signaling protein in certain cancer cells.
  2. Growth signals increase: The abnormal protein activates pathways that encourage cancer-cell growth and survival.
  3. Alectinib inhibits ALK: Alectinib binds to and inhibits ALK kinase activity.
  4. Cancer signaling is reduced: Blocking ALK interferes with important growth and survival signals.
  5. Tumor growth may be controlled: In responsive cancers, this can slow cancer progression or reduce tumor size.

The treatment does not guarantee that cancer will disappear. Its effectiveness depends on the cancer’s molecular characteristics, treatment history, individual health factors and response to therapy.

Alecnib 150 mg Product Information

The following table summarizes the product identity presented on this website.

Product detailInformation
Product nameAlecnib
Stated strength150 mg
Active ingredientAlectinib
Therapeutic categoryAnticancer medicine
Drug classALK tyrosine kinase inhibitor
Main treatment areaALK-positive NSCLC
Route of administrationOral, for the established alectinib reference formulation
ManufacturerRequires product-specific confirmation
Regulatory statusDepends on the specific product and country

The reference alectinib product is supplied as 150 mg capsules. The dosage form of Alecnib itself should be confirmed from its packaging and accompanying leaflet.

Dosage and Administration

Alectinib dosage is determined by the treatment indication, the applicable product label, tolerability and the patient’s medical condition.

For the U.S. reference product, the usual adult dose is:

Usual adult reference-product dose

600 mg

Twice daily with food

When using 150 mg capsules, this reference dose corresponds to four capsules per dose, taken twice daily. This is not an individualized instruction for Alecnib.

Important administration principles include:

  • Take alectinib with food.
  • Follow the exact dose prescribed by the oncology specialist.
  • Swallow capsules whole if using the capsule formulation.
  • Do not open, crush or dissolve capsules unless the applicable product instructions specifically permit it.
  • Take doses at the prescribed times each day.
  • If a dose is missed, follow the applicable product leaflet; do not double the next dose.
  • If vomiting occurs after taking a dose, do not take an additional replacement dose unless instructed by the healthcare professional.

Dose interruptions and reductions may be necessary if significant adverse reactions occur. Patients should not change their dose independently.

Important Safety Information

Alectinib can cause side effects ranging from mild symptoms to serious complications. Patients require medical supervision throughout treatment.

Important safety concerns include:

Liver problems

Alectinib can cause liver injury and abnormalities in liver-function tests.

Healthcare professionals generally monitor liver enzymes and bilirubin during treatment. Patients should report symptoms such as yellowing of the skin or eyes, dark urine, unusual tiredness, abdominal discomfort or loss of appetite.

Lung inflammation

Interstitial lung disease or pneumonitis can occur.

Symptoms may include new or worsening cough, shortness of breath, chest discomfort or fever. These symptoms require prompt medical assessment.

Slow heart rate

Alectinib may cause bradycardia, meaning an unusually slow heart rate.

Patients should report dizziness, fainting, unusual weakness or symptoms that may indicate an abnormal heart rhythm.

Muscle problems

Alectinib may cause muscle pain, tenderness, weakness or increased creatine phosphokinase (CPK) levels.

Unexplained or severe muscle symptoms should be reported to the treating healthcare professional.

Kidney problems

Kidney impairment has been reported in patients receiving alectinib. Monitoring may be required, particularly when symptoms or laboratory findings suggest reduced kidney function.

Anemia and red blood cell problems

Alectinib can be associated with anemia and, in some cases, hemolytic anemia. Unusual fatigue, pale skin, breathlessness or yellowing of the skin should be assessed.

Pregnancy and breastfeeding

Alectinib may cause harm to an unborn baby. Pregnancy status, contraception and family-planning considerations should be discussed with the oncology team before and during treatment.

Breastfeeding is not recommended during treatment under the U.S. reference-product instructions. Patients should consult the applicable label for guidance about the period after treatment.

Common Side Effects

Some adverse reactions reported with alectinib include:

  • Fatigue
  • Constipation
  • Muscle pain
  • Swelling of the hands, feet or ankles
  • Anemia
  • Nausea
  • Rash
  • Increased bilirubin
  • Increased liver enzymes
  • Increased CPK levels

The frequency and severity of side effects can vary between patients.

Not everyone experiences the same reactions. Some effects can be managed with monitoring, supportive treatment or a clinician-directed dose adjustment.

Monitoring During Alecnib Treatment

Regular medical follow-up is important when receiving alectinib.

Depending on the patient’s condition, monitoring may include:

Monitoring areaPurpose
Liver functionIdentify possible liver injury
Heart rateDetect clinically significant bradycardia
Muscle symptoms and CPKAssess possible muscle injury
Kidney functionIdentify possible renal complications
Blood countsAssess anemia and other blood abnormalities
Respiratory symptomsIdentify possible lung inflammation
Pregnancy status, where relevantAddress embryo-fetal risk
Cancer imagingEvaluate treatment response and disease progression

The U.S. reference-product label provides specific monitoring instructions, including regular liver-function testing during the first months of treatment and CPK monitoring during the initial treatment period. The treating specialist should follow the current applicable label.

Who Should Use Alecnib?

Alectinib may be appropriate for patients who meet the approved treatment criteria for ALK-positive NSCLC.

Before treatment, the oncology team generally considers:

  • Confirmed ALK-positive tumor status.
  • The stage and characteristics of the cancer.
  • Previous cancer treatments.
  • Liver and kidney function.
  • Heart rate and relevant medical history.
  • Other prescription and non-prescription medicines.
  • Pregnancy and breastfeeding considerations, where applicable.
  • The patient’s ability to tolerate the treatment.

Alectinib is not appropriate for every patient with lung cancer. Treatment suitability must be assessed by a qualified oncology professional.

Drug Interactions

Alectinib may interact with other medicines and substances.

Its metabolism involves the CYP3A4 enzyme system. Certain medicines that affect this pathway may change alectinib exposure.

Patients should tell their healthcare professional about all medicines they use, including:

  • Prescription medicines.
  • Over-the-counter medicines.
  • Herbal products.
  • Vitamins and supplements.
  • Medicines used for infections.
  • Medicines used for heart conditions.
  • Other anticancer treatments.

Patients should not start or stop another medicine without checking with their healthcare team.

Important Precautions Before Treatment

Before starting alectinib, patients should discuss their medical history with their oncology specialist.

Important considerations include:

  • Previous liver disease.
  • Kidney impairment.
  • Slow heart rate or heart rhythm problems.
  • Existing muscle disorders.
  • Previous lung inflammation.
  • Pregnancy or plans to become pregnant.
  • Breastfeeding.
  • Current medicines that may interact with alectinib.

These precautions help the healthcare team assess treatment suitability and plan appropriate monitoring.

Frequently Asked Questions About Alecnib

What is Alecnib 150 mg?

Alecnib is identified on this website as a product containing alectinib, with a stated strength of 150 mg. Alectinib is a targeted anticancer medicine used for specific patients with ALK-positive non-small cell lung cancer.

What is the active ingredient in Alecnib?

The active ingredient identified for Alecnib is alectinib. It belongs to the ALK tyrosine kinase inhibitor class of medicines.

Is Alecnib used for all types of lung cancer?

No. Alectinib is used for specific ALK-positive forms of non-small cell lung cancer. Appropriate molecular testing is required to establish eligibility.

How does alectinib fight cancer?

Alectinib blocks abnormal ALK signaling that can support cancer-cell growth and survival. This may help slow or control the growth of responsive cancer cells.

Is Alecnib chemotherapy?

Alectinib is not conventional chemotherapy. It is a targeted therapy that works by inhibiting abnormal ALK protein activity.

Can alectinib treat brain metastases?

Alectinib can reach the central nervous system and has activity against certain brain metastases in ALK-positive NSCLC. Treatment response varies and requires specialist assessment.

Should alectinib be taken with food?

The established reference alectinib capsule instructions specify taking the medicine with food. Patients should follow the instructions supplied with their exact prescribed product.

What are the common side effects of alectinib?

Commonly reported effects include fatigue, constipation, muscle pain, swelling, anemia and abnormalities in liver-function tests or CPK levels.

Does alectinib require regular blood tests?

Yes. Monitoring may include liver-function tests, CPK measurements, blood counts and kidney-function assessments, depending on the patient’s condition and treatment instructions.

Can Alecnib be stopped when symptoms improve?

Patients should not stop alectinib independently because symptoms improving does not necessarily mean the cancer is controlled. Treatment decisions must be made with the oncology specialist.

Final Overview

Alecnib is identified on this website as an alectinib-containing product with a stated strength of 150 mg. Alectinib is an important targeted therapy for eligible patients with ALK-positive non-small cell lung cancer.

By inhibiting abnormal ALK signaling, alectinib can help control cancer growth in patients whose tumors are sensitive to this treatment. Its use requires appropriate molecular testing, a specialist-directed prescription, regular monitoring and careful management of potential adverse reactions.

Patients should confirm the exact Alecnib formulation and product details from its packaging and official documentation. Treatment should always be guided by a qualified oncology professional.

Medical Disclaimer: This page is intended for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Alecnib should not be started, stopped or adjusted without guidance from a qualified healthcare professional.